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Background: Current guidelines recommend repeated doses of albuterol for the
emergency treatment of acute asthma. However, approximately one-third of patients
show little or no initial response to this partial b2-agonist.
Methods: We conducted a randomized, double-blind, proof-of-concept study to investi-
gate whether a full b2-agonist, isoproterenol, offers a therapeutic advantage in adults
presenting with acute severe asthma (FEV1o50%) who fail to respond to an initial
treatment of the partial b2-agonist, albuterol. Study subjects were randomized to receive
a 2-h continuous nebulization of either albuterol (7.5mg/h) (n ¼ 10, mean FEV1 ¼ 37%
predicted) or isoproterenol (7.5mg/h) (n ¼ 9, mean FEV1 ¼ 33% predicted). Respiratory
symptoms, vital signs and pulmonary function measures were collected.
Results: Subjects from both treatment groups had similar baseline characteristics. The
percent improvements from baseline FEV1 at 60 and 120min were significantly higher in
subjects receiving isoproterenol than those receiving albuterol (44 vs. 17% and 63 vs. 24%,
respectively, Po0.05). The change in symptoms measured by the modified Borg score was
also significantly greater in subjects receiving isoproterenol (Po0.01). Both treatments
were well tolerated, though the mean increase in pulse rate at 60 and 120min (21 vs. 1 and
23 vs. 6 beats/min, respectively, Po0.05) and the mean change in serum potassium atElsevier Ltd. All rights reserved.
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N.A. Hanania et al.1008120min (0.52 vs. 0.07meq/L, Po0.05) from baseline were significantly greater in the
isoproterenol group.
Conclusions: Our data suggest that in subjects presenting with acute severe asthma who
fail to show an initial response to albuterol, the use of a b2-agonist of higher intrinsic
efficacy can be more effective in improving lung function and symptoms.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Asthma is a common chronic inflammatory disease of the
airways with significant morbidity and mortality.1,2 Con-
siderable progress has been made in understanding the
pathogenesis of asthma and improving its treatment.
Despite improvements in the outpatient care of asthma,
the emergency treatment of acute asthma remains inade-
quate.3,4 Among the 2 million patients presenting to US
hospital emergency departments (ED) with acute exacerba-
tions every year, approximately one-third fail to show
sufficient improvement to allow safe discharge, and instead
require admission to the hospital and sometimes to the
intensive care unit.1–6
Prompt management of acute asthma is essential to
prevent complications.3,4 Managing patients with acute
asthma involves assessing the severity of exacerbation,
implementing measures to rapidly reverse airflow limita-
tion, and instituting therapies such as systemic corticoster-
oids to limit the progression of airway inflammation.7 b2-
Adrenergic agonists are the most powerful bronchodilators
known, and their use is a mainstay of the initial treatment of
acute exacerbation of asthma.7 Despite more than a century
of drug development and the current availability of
numerous b2-agonists of widely differing pharmacologic
properties, the optimal use of these agents in the manage-
ment of asthma is not fully determined.
b2-agonists are generally classified by their receptor
selectivity, duration of action, affinity, potency and intrinsic
efficacy.8–10 Intrinsic efficacy refers to the ability of a drug,
independent of tissue conditions, to interact with a receptor
to activate its downstream signal transduction pathway. It
serves as a measure of the relative agonism of a drug or a
hormone—i.e., a partial agonist is less effective than a full
agonist in causing a downstream cellular response once
bound to its receptor at equal receptor occupancy. The
measurement of intrinsic efficacy has uncovered dramatic
differences between drugs used clinically that had not been
previously apparent in many studies of comparative efficacy.
A simple formula to determine the intrinsic efficacy of a b2-
agonist based on measurements of affinity (dissociation
constant, KD) and potency (EC50) has recently been
reviewed.10 The intrinsic efficacy of the most widely used
b2-agonist for the emergency treatment of acute asthma,
albuterol, is only 5% that of epinephrine or isoproterenol,
which are considered full b2-agonists.
10–12
Current asthma guidelines recommend repeated doses of
albuterol, as needed, for the initial emergency treatment of
acute asthma,7 but do not recommend stepping up therapy
to an agonist of higher intrinsic efficacy in patients who fail
to adequately respond to albuterol. We hypothesized that
the use of b2-agonists of high intrinsic efficacy (full agonist)may lead to better outcomes in the emergency treatment of
patients with acute severe asthma who fail to show an initial
response to a partial agonist. To address this issue, we
initiated a randomized, double-blind, proof-of-concept
study to compare the full b2-agonist, isoproterenol, with
the partial b2-agonist, albuterol, in acute severe asthma.
The results of this study have previously been reported in
part in the form of an abstract.13
Methods
Study subjects
Adults (18–50 years old) presenting with acute asthma to
Ben Taub General Hospital’s ED in Houston during the years
1998–2000, were screened for enrollment. Subjects were
required to have a history of physician-diagnosed asthma for
at least 6 months, be non-smokers or have past history of
smoking o10 pack years, and have an FEV1o50% of
predicted after one initial therapy with nebulized albuterol
(2.5mg) administered in the ED on arrival. Subjects with
significant comorbid conditions, those with other respiratory
conditions, pregnant women, and those suffering from a
life-threatening exacerbation such as those with impending
respiratory failure (severe hypercapnia or hypoxemia),
hemodynamic compromise, or those needing ICU admission,
intubation or non-invasive ventilation were excluded. The
study was approved by Baylor College of Medicine’s
Institutional Review Board, and all subjects gave written
informed consent to participate.
Study design
This was a single center, double-blind, randomized parallel
group study. Subjects who met the eligibility criteria were
randomized in a double-blind fashion to receive either
albuterol sulfate 0.083% solution (7.5mg/h) (Dey Inc, Napa,
CA) or isoproterenol 1:200 solution (7.5mg/h, Sanofi
Winthrop Pharmaceuticals, NY). Randomization was per-
formed locally by the hospital’s research pharmacy. The
study medications were preservative free and were diluted
in 20mL of saline and administered over 2 h by continuous
nebulization using an Airlife Misty Max 10TM nebulizer. All
study subjects received prednisone 60mg orally upon
randomization and continuous oxygen 3 L/min by nasal
cannula.
Efficacy measures
Serial peak flow meter (PEFR) measurements were per-
formed using a Wright peak flow meter every 30min, and
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was performed and interpreted in accordance with the
reproducibility and acceptability criteria of the American
Thoracic Society14 using a Puritan Benett model PB-100
portable spirometer. Peak flow and lung function measure-
ments were performed by the same person throughout the
study visit. The severity of dyspnea was assessed every
15min using the modified Borg score (0–10) with 0 being
asymptomatic, 10 being very severe symptoms.15 The
primary endpoint of the study was the mean percent change
in FEV1 from baseline at 60min following the administration
of study medications. Other efficacy measures included the
mean percent change in FEV1 from baseline at 120min,
percent of subjects who achieved a 20% improvement in
baseline FEV1 at 60min, mean percent change in PEFR from
baseline at 60 and 120min, mean change in modified Borg
scores, and disposition status from the ED.Safety measures
Study subjects were continuously monitored in a dedicated
research area and vital signs were monitored every
15min. All subjects had continuous electrocardiographic
and pulse oximetry monitoring. A 12-lead EKG was
performed and serum potassium (K+) was measured at the
beginning and the end of the study (0 and 120min). A
subject was withdrawn from the study if he/she experienced
significant worsening of symptoms, tachycardia 4160
beats/min or any tachyarrhythmias. Subjects withdrawn,
were followed and their last evaluable data were included in
the analysis under intent-to-treat. At the end of the 2 h of
monitoring, study subjects were managed by the ED
physician but were followed by study personnel until a
disposition decision was made.80
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Figure 1 Effect of continuous nebulization of isoproterenol
and albuterol on the mean (SE) percent change in FEV1 at 60 and
120min compared to baseline. At each time point isoproterenol
resulted in a significantly higher improvement in FEV1 compared
to albuterol. SE ¼ standard error, *Po0.05.Statistical analysis
We initially planned the study to enroll 50 subjects in each
arm based on a power analysis that was based on an
estimated 30% difference in percent improvement in FEV1
between the two treatment groups with 0.95 confidence and
power of 0.8. Our plan was aborted by the fact that
isoproterenol inhalation solution was discontinued
from the US market during the conduct of the study.
Baseline characteristics of the two treatment groups
were compared using Student’s t-test for continuous
variables and the w2-test for categorical variables. We used
an analysis of variance (ANOVA) model to compare changes
in the measured efficacy and safety variables from baseline
over time in each of the treatment groups, and used an
unpaired t-test to compare the measured variables at each
time point between the two treatment groups. When the
primary assumption of equal variance between the two
treatment groups did not hold, we used the Wilcoxon rank-
sum test to compare between groups. Change in the
Borg score over time was evaluated by repeated-measures
mixed-model analysis of variance (SAS version 8.2), with
main effects of time and treatment, as well as the
first-order interaction. Significance was imparted at the
Po0.05 level.Results
Study subjects
A total of 56 subjects were screened for enrollment, and 19
met the inclusion criteria and were randomized to receive
study medications. The major reason for exclusion from the
study was failure to meet the spirometry criteria
(FEV1o50%). Ten subjects (5 African-American, 4 Hispanic,
1 Caucasian) were randomized to albuterol and 9 subjects
(8 African-American, 1 Hispanic) to isoproterenol. Baseline
characteristics were similar in both treatment groups except
for some difference in the ethnic mix of the subjects as
noted above. Of note is the underutilization of maintenance
inhaled corticosteroids in both groups as well as the
frequent ED visits for asthma in the preceding year which
are common findings in inner city asthma patients in the US.
Physiologic response
Mean percent improvements from baseline FEV1 at 60min
(44% vs. 17%) and 120min (63% vs. 24%) were significantly
higher in subjects receiving isoproterenol than in those
receiving albuterol (Po0.05) (Fig. 1). Improvements in PEFR
were also higher at all time points measured in the group
receiving isoproterenol, but these changes did not reach
statistical significance (Table 2). Six of the nine subjects
receiving isoproterenol (66%) vs. 4 of the 10 subjects
receiving albuterol (40%) had a change in FEV1420% in the
first hour, while 3 patients receiving albuterol (30%) had a
decline in their FEV1 from baseline in the first hour
compared to none of the subjects receiving isoproterenol.
Similar superiority of response with isoproterenol was noted
during the second hour of treatment.
Symptomatic response
Although the mean Borg score was higher in the isoproter-
enol group than in the albuterol group at baseline (Table 1),
ARTICLE IN PRESS
Table 1 Baseline characteristics of study subjects.
Isoproterenol (n ¼ 9) Albuterol (n ¼ 10)
Men (n) 5 3
Age in years, mean, (range) 27.6 (18–41) 31.1 (20–47)
Age at asthma diagnosis, years (SD) 12.3 (8.8) 11.8 (14.2)
Hospitalization in past year (n) 3 3
ED visit in past year (n) 6 6
Past smoker (n) 3 2
SABA use (n) 9 10
LABA use (n) 1 1
ICS use (n) 3 2
SaO2 , mean (range) 94.7 (91–98) 95.9 (93–99)
Modified Borg score, mean (range) 5.5 (3–10) 3.8 (1–7)
Pulse rate (beats/min), mean (range) 104 (83–132) 106.8 (79–130)
PEFR (L/min), mean, (SD) 157.2 (43.8) 148.5 (52.1)
FEV1 (L), mean (SD) 1.06 (0.33) 1.14 (0.37)
% Predicted FEV1, mean (range) 33.3 (23–46) 37 (18–48)
Serum K+ (meq/L), mean (SD) 4.1 (0.32) 3.6 (0.44)
QTc interval (ms), mean (SD) 409 (37) 427 (35)
Po0.05, albuterol vs. isoproterenol, SABA ¼ short-acting beta-agonists, LABA ¼ long-acting beta-agonists, ICS ¼ inhaled,
corticosteroids, SD ¼ standard deviation.
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Figure 2 Effect of continuous nebulization of isoproterenol
and albuterol on mean change in modified Borg score (SE) from
baseline t 60 and 120min. At all time point after 45min,
isoproterenol resulted in a significantly larger symptom reduc-
tion compared to albuterol. SE ¼ standard error, *Po0.05.
N.A. Hanania et al.1010however, it dropped rapidly with therapy, crossing the
albuterol group at 45min, and remaining well below at all
time points until the end of observation at 120min. Mean
scores at 45, 60, 75, 90,105 and 120min were statistically
lower in the isoproterenol-treated subjects compared to
those treated with albuterol (Fig. 2) (Po0.05). Time effect
was highly significant (Po0.0001) and time treatment
interaction was also significant at Po0.05 (Table 2).Safety parameters
Safety parameters measured at 60 and 120min during the
study are outlined in Table 3. The mean change in heart ratefrom baseline was significantly higher at 60 and 120min in
the isoproterenol group compared to the albuterol group (21
vs. 1 and 23 vs. 6 beats/min, respectively, Po0.05). More
subjects receiving isoproterenol had tachycardia
(4100 beats/min) than those receiving albuterol. Only one
subject receiving isoproterenol was discontinued from the
study for safety purposes because of a heart rate 4160
beats/min. The mean decrease in serum K+ at 120min from
baseline was also significantly greater in the isoproterenol
group compared to the albuterol group (0.52 vs.
0.07meq/L, Po0.05). There were no significant changes
between the two groups in systolic and diastolic blood
pressure, oxygen saturation measured by pulse oximetry,
and QTc measurements over the 2 h of the study.
Disposition from the ED
All patients except one (mentioned above) completed the
120min study. Four patients in the albuterol group vs. two in
the isoproterenol group were admitted to the hospital. The
decision to admit the patient to the hospital was made by
the ED physician and was based on the overall status of the
patient after completion of the study.
Discussion
In this proof-of-concept study we demonstrated that in
subjects presenting to the ED with acute severe asthma who
fail to show an initial response to a b2-agonist of low
intrinsic efficacy (the partial agonist, albuterol), a b2-
agonist of high intrinsic efficacy (the full agonist, isoproter-
enol), was more effective in improving lung function and
symptoms. However, although both treatments were well
tolerated by the study subjects, the use of an agonist of high
ARTICLE IN PRESS
Table 3 Safety parameters measured at 60 and 120min.
Isoproterenol (n ¼ 9) Albuterol (n ¼ 10)
60min
Heart rate (beats/min) 125 (5) 109 (4)
Heart rate o100/min (n) 0 3
Heart rate 100–120/min(n) 2 5
Heart rate 120–140/min (n) 6 2
Heart rate 140–160/min (n) 1 0
Systolic BP (mmHg) 130 (6) 130 (6)
Diastolic BP (mmHg) 79 (5) 77 (4)
SaO2% 94 (3) 95 (2)
120min
Heart rate 127 (6) 115 (7)
Heart rate o100/min (n) 0 3
Heart rate 100–120/min (n) 4 4
Heart rate 120–140/min (n) 4 2
Heart rate 140–160/min (n) 1 1
Systolic BP (mmHg) 138 (6) 127 (4)
Diastolic BP (mmHg) 80 (4) 73 (4)
SaO2% 93 (2) 94 (2)
QTc (ms) (range) 420 (352–484) 418 (340–472)
Serum K+ (meq/L) (range) 3.6 (3.1–3.9) 3.5 (2.7–4.4)
Data values are mean (SE) except when mentioned otherwise, SE ¼ standard error, SaO2% ¼ percent oxygen saturation measured by
pulse oximetry. K+ ¼ potassium.
Po0.05.
Table 2 Change in measures of lung function and symptoms from baseline at 60 and 120min.
Isoproterenol (n ¼ 9) Albutertol (n ¼ 10) P-value
D at 60min
% D in FEV1 (SE), 44 (8) 17 (9) 0.046
% D in PEFR (SE) 48 (11) 30 (11) 0.27
D in modified Borg score (SE) 4 (0.5) 1 (0.7) 0.04
D at 120min
% D in FEV1 (SE) 63 (9) 24 (9) 0.01
% D in PEFR (SE) 67 (13) 41 (9) 0.12
D in modified Borg score (SE) 5 (0.8) 3 (0.5) 0.02
Data values are mean (SE), SE ¼ standard error, PEFR ¼ peak expiratory flow rate, FEV1 ¼ forced expiratory volume in first second.
b2-agonists in acute asthma 1011intrinsic efficacy may be associated with an increased
incidence of adverse effects such as hypokalemia and
tachycardia due to activation of b2-receptors in non-target
sites.
Historically, isoproterenol, a non-selective b-agonist of
high intrinsic efficacy was the first agent to be widely used
via nebulization.8,16 Albuterol was introduced in the US in
1984. Like isoproterenol, it has a rapid onset of action but
unlike isoproterenol, it is more than 1000 fold functionally
selective for the b2 -receptor subtype over the b1 subtype.
9
Because of its excellent safety profile and quick onset of
action, albuterol delivered either by nebulization or inhaler
devices has largely replaced the non-selective b-agonists,
isoproterenol and epinephrine, in the treatment of acuteasthma exacerbations.17 Even though albuterol is a partial
agonist, clinical data indicate that it is effective in relieving
acute bronchospasm in most patients with mild-to-moderate
asthma exacerbation, and may be as effective as subcuta-
neous epinephrine in this situation.18 This paradox, that two
drugs with markedly different intrinsic efficacies can none-
theless have similar clinical efficacies, can be explained by
understanding the effects of receptor numbers and func-
tional antagonism on cellular responses. Airway smooth
muscle cells, which express high levels of b2-adrenergic
receptors, have more receptors than are necessary to fully
activate downstream responses in normal situations (‘‘spare
receptors’’). Thus, even though albuterol has a low intrinsic
efficacy, it is able to elicit a comparable downstream
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and low functional antagonism such as the case in mild
asthma exacerbations.10 However, clinical studies indicate
that up to one-third of patients with acute severe exacer-
bation have poor or no initial response to therapy and may
require prolonged and aggressive therapy, hospital admis-
sion, intubation and mechanical ventilation.5,6 In such
situations, b2-adrenoceptors may be functionally antago-
nized by inflammatory mediators and there may be fewer
‘‘spare’ receptors due to desensitization from the use of
multiple doses of rescue b2-agonist at home.
19–21 The
submaximal efficacy of a partial agonist such as albuterol
may only become apparent in this setting, and a full agonist
may have a therapeutic advantage (Fig. 3).10
Despite this potential therapeutic advantage for using
high intrinsic efficacy b2-agonists in certain asthma settings,
only few studies have addressed the clinical utility of such
agents in severe asthma exacerbation. In a multicenter,
randomized, double-blind, placebo-controlled study, pa-
tients with acute asthma receiving inhaled fenoterol (an
agonist with high intrinsic efficacy) had significantly more
improvement in airflow than those receiving inhaled
albuterol.22 In another small study from Japan, children
suffering from acute severe asthma not responding to
conventional therapy were successfully treated with con-
tinuous nebulization of isoproterenol.23 A more recent study
demonstrated superiority of formoterol, a b2-agonist of
relatively high intrinsic efficacy (40% that of isoproter-
enol10) over albuterol in acute severe asthma.24 Our study is
in agreement with these studies as it demonstrates an
advantage of using a b2-agonist of high intrinsic efficacy in aFigure 3 Schematic representation for the potential differential e
muscle during remission and during an acute severe exacerbation of
cytokines results in attenuation of beta-agonist signalling.situation when airway obstruction is severe despite the use
of a b2-agonist of low intrinsic efficacy, such as albuterol.
However, the administration of high intrinsic efficacy
b2-agonists cannot be routinely justified for every patient
with acute asthma because they can potentially activate
receptors in non-target sites such as the heart and skeletal
muscles and their use in high doses may be associated with
an increased incidence of adverse effects. This was clearly
demonstrated in the study comparing fenoterol with
albuterol in the acute setting described above22 as well as
in our study although the increase in heart rate observed
with isoproterenol in our study may also be secondary to
activation of cardiac b1 receptors. The risk–benefit ratio in
specific settings will need to be further defined in future
clinical trials. In addition, in vitro studies indicate that
b2-agonists with high intrinsic efficacy may induce more
receptor desensitization than those with low intrinsic
efficacy.10 This fact is also supported by some in vivo
studies25,26 but not by others.27 For example, desensitiza-
tion to the bronchodilator effects of formoterol, a long-
acting b2-agonist of relatively high intrinsic efficacy, has
been observed with its regular use in some studies,25
whereas it has not been shown with the regular use of
salmeterol, a long-acting b2-agonist of very low intrinsic
efficacy.26
Our study has certain limitations. We enrolled a small
number of subjects in this study because of the discontinua-
tion of the study medication, isoproterenol solution, from
the US market during the study. Our findings need to be
confirmed in additional trials using other b2-agonists of high
intrinisic efficacy to be certain that the superior clinicalffects between full and partial beta-agonists on airway smooth
asthma; note that the line indicating functional antagonism by
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some other pharmacologic properties of isoproterenol. For
safety purposes, we were only able to screen and enroll
subjects who had already received an initial dose of
albuterol and therefore could not evaluate the initial
response to both agonists upon arrival in the ED. However,
we believe that our study population represents the one
which may benefit from treatment with a full agonist as
opposed to a partial agonist. We used similar doses for both
albuterol and isoproterenol despite the fact that these
agonists have different potencies (isoproterenol4albuterol).
However, in a previous study on a similar patient population
with acute asthma, there was no documented advantage
from administering albuterol in a higher dose than what we
used (7.5mg/h28). Thus, we believe that the difference in
potency in this situation did not influence our findings.
Several other factors which include the pre-hospital use of
asthma medications such as inhaled corticosteroids or
b2-agonists and genetic factors such as b-receptor poly-
morphisms, may have influenced the bronchodilator
response in our subjects. While these confounders are
corrected for by the similar baseline characteristics in both
treatment groups, the ethnic mix of our patient population
was not identical as we had slightly more African-American
patients in the isoproterenol group. Future studies need to
perform genetic analyses to determine whether receptor
genotype or haplotype may influence the response to
b-agonists of different intrinsic efficacy in acute asthma.
In conclusion, our study results suggest that in subjects
presenting to the ED with acute severe asthma who fail to
show an initial response to a b2-agonist of low intrinsic
efficacy, a b2-agonist of high intrinsic efficacy can be more
effective in improving lung function and symptoms. This
pharmacologic characteristic needs to be considered in
future studies and in the development of new b2-agonists for
the treatment of acute asthma.Acknowledgments
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